致力于岭南药用植物中抗炎、抗肿瘤活性小分子的发现与研究。已完成30余种生物资源(8种为国际上首次)的化学成分研究。共分离鉴定500余个化合物，其中新化合物200余个，含10种新颖骨架类型。发现具有显著生物活性的新化合物30多个。发表通讯或第一作者SCI论文53篇(通讯38篇)，总IF=165.7，其中9篇（如OL，JMC等）发表在该领域top杂志(平均IF>5.0)，单篇论文最高他引74次，1篇论文入选ACS亮点专辑，3个新骨架被Nat. Prod. Rep. (IF=10.99)选为热点化合物，5个新化合物因活性显著被点评，6个新化合物被他人全合成。曾获中科院院长特别奖，现主持"863"青年科学家专项、广东省杰青、国自然面上等基金。本项目以前期发现的强效Pgp抑制剂jatrophane大环二萜为基础，拟对其进行结构优化及成药性评估，为逆转肿瘤多药耐药的新药研发奠定基础。

Sheng Yin’s research interest focuses on the discovery of anti-inflammatory and anti-tumor constituents from Lingnan herbs. He has systematically investigated the chemistry of more than 30 natural species, among which 8 were reported for the first time. More than 500 natural products have been isolated so far, in which 200 compounds were new, including ten types of novel skeletons. 30 new compounds were found remarkable bioactivities. So far, he has published 53 SCI research papers as corresponding or 1st author (38 papers were listed as corresponding author), 9 of which were published in the top journals of this area, such as OL, JMC. One paper has been cited 74 times by others; One paper has been highlighted by ACS Virtual Issue; Three novel compounds were selected as “Hot off the press” by Nat. Prod. Rep. (IF=10.99), while 5 new compounds attracted attention of this journal; Six new compounds were total synthesized by other research groups. He has won many rewards such as “The special prize of president scholarship from Chinese Academy of Sciences", and also got financial support from “863 young scientist” Program of China, Guangdong Natural Science Funds for Distinguished Young Scholar, National Natural Science Foundation of China. The proposed project will focus on the structural optimization and druggability assessment of a group of potent Pgp inhibitors, jatrophane diterpenoids, found in previous study. This research will hopefully pave a way for drug development in tumor multi-drug resistance therapy.

天然产物由于具有结构多样性和生物活性多样性的特点，是创新药物研究中发现先导分子的重要来源。本项目以天然产物基础和应用研究为研究目标，建立了结合天然产物化学、计算生物学、分子生物学、药理学多学科交叉研究团队、技术平台和人才队伍，围绕天然药物资源中新类型、新结构的天然产物的发现和活性研究，取得了以下成绩：（1）对马鞭草科、车前科、益母草属以及五味子科等10余种药用植物的化学成分进行了研究，分离得到了500余个天然产物，包括100余个新的结构；（2）通过活性筛选，发现了系列具有抗HIV、精神性疾病、肿瘤以及在抗炎免疫等方面的系列天然产物活性分子，结构类型涉及到二萜、三萜以及生物碱等类型，为进一步的新药研发提供科学依据和研究基础；（3）初步完成了抗HIV活性分子“二苯胺酯”成药性评价，研究表明该目标分子是很有开发前景的抗HIV候选药物，作用机理研究表明化合物“二苯胺酯”抑制病毒（＋）链DNA的合成，为新的作用机制，相关研究已经申请了专利进行保护，拥有自主知识产权；（4）共发表SCI论文16篇，其中13篇为通讯作者，2项专利获得授权。（5）培养博士生1名、硕士生3名，另外1名博士研究生和2名硕士研究生已经完成了研究工作，将于2018年夏季申请毕业答辩；项目五味子化学于2015年获得了云南省自然科学科学技术奖特等奖（排名第4）；项目负责人获得了中国科学院王宽诚西部学者突出贡献奖（2015年）、中国药学会赛诺菲生物药物奖（2015）以及入选了中国科学院首批青年创新促进会优秀会员等奖项和荣誉。